Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2019 | 12-2017 | 12-2006 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -76,124 | -51,400 | N/A | N/A |
| Depreciation Amortization | 11,208 | 6,661 | N/A | N/A |
| Accounts receivable | 117 | 491 | N/A | N/A |
| Accounts payable and accrued liabilities | 10,426 | -3,474 | N/A | N/A |
| Other Working Capital | 12,691 | 3,485 | N/A | N/A |
| Other Operating Activity | -6,286 | 12,158 | 0 | 0 |
| Operating Cash Flow | $-47,968 | $-32,079 | $N/A | $N/A |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -1,364 | -1,810 | N/A | N/A |
| Investing Cash Flow | $-1,364 | $-1,810 | $N/A | $N/A |
| Cash Flows From Financing Activities | ||||
| Debt Issued | 46,813 | 40,000 | N/A | N/A |
| Debt Repayment | -5,458 | -6,192 | N/A | N/A |
| Common Stock Issued | 136,877 | N/A | N/A | N/A |
| Other Financing Activity | -11,776 | 9,518 | 0 | 0 |
| Financing Cash Flow | $166,456 | $43,326 | $N/A | $N/A |
| Beginning Cash Position | 11,540 | 2,103 | N/A | N/A |
| End Cash Position | 128,664 | 11,540 | N/A | N/A |
| Net Cash Flow | $117,124 | $9,437 | $N/A | $N/A |
| Free Cash Flow | ||||
| Operating Cash Flow | -47,968 | -32,079 | N/A | N/A |
| Capital Expenditure | -1,364 | -1,810 | N/A | N/A |
| Free Cash Flow | -49,332 | -33,889 | 0 | 0 |